Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation

Appoints Internationally Renowned Scientific Advisors

COPENHAGEN, Denmark— 8 February 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and is due to start in March 2018. Acesion also announces the appointment of internationally renowned AF experts as scientific advisors.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...